title: Vasoactive role for angiotensin II type 2 receptors in human radial artery.
abstract: Angotensin II type 2 receptors are believed to counter the effects of the angiotensin type 1 receptors and there is no data relating to the co-localisation of either receptor in human diseased arteries. We sought to determine whether AT2R counter the effects of AT1R and immunolocalise both receptors to cells in human diseased arteries. Human radial arteries (RA, n=11) were placed in organ bath chambers and preincubated with the AT2R antagonist PD123319 for twenty minutes before an angiotensin II dose response curve. Immunohistochemistry was performed to identify receptors and pathology was quantified by image analysis software. We observed both receptors in human arteries. Angiogenic blood vessels within occluded arteries expressed both receptors. PD123319 impaired angiotensin II mediated vasoconstriction by 20 percent (n=5, p less than 0.05), however in other arteries, PD123319 exacerbated angiotensin II-mediated vasoconstriction by 60 percent (n=6, p less than 0.01), respectively. We conclude that inhibition of AT2R can enhance or reduce angiotensin II-mediated vasoconstriction. These data indicate that the role of AT2R in human diseased arteries is divergent although the AT2R-mediated vasorelaxation prevails.
authors.affiliation: College of Health and Biomedicine, Victoria University, St Albans, Australia.
authors.forename: A
authors.initials: A
authors.lastname: Zulli
authors.affiliation: Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Australia.
authors.forename: D L
authors.initials: DL
authors.lastname: Hare
authors.affiliation: Departments of Cardiac Surgery, Austin Health, Heidelberg, Australia.
authors.forename: B F
authors.initials: BF
authors.lastname: Buxton
authors.affiliation: Department of Pharmacology, Monash University, Australia.
authors.forename: R E
authors.initials: RE
authors.lastname: Widdop
mesh_terms: D057912:Angiotensin II Type 2 Receptor Blockers / Q000494:pharmacology; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D011725:Pyridines / Q000494:pharmacology; D017534:Radial Artery / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism; D044139:Receptor, Angiotensin, Type 2 / Q000378:metabolism*; D014661:Vasoconstriction / Q000187:drug effects* / Q000502:physiology; D014664:Vasodilation / Q000187:drug effects* / Q000502:physiology
chemical_list: D057912:Angiotensin II Type 2 Receptor Blockers; D007093:Imidazoles; D011725:Pyridines; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; C073402:PD 123319